|
?:authorAffiliation
|
-
[\'Vaccine and Infectious Diseases Division, Fred Hutch Cancer Research Center, Seattle, Washington, USA.\', \'Division of Allergy and Infectious Diseases, Department of Medicine, University of Washingtongrid.34477.33, Seattle, Washington, USA.\', \'Department of Epidemiology, University of North Carolina at Chapel Hillgrid.10698.36, Chapel Hill, North Carolina, USA.\', \'Vir Biotechnology, San Francisco, California, USA.\', \'Department of Laboratory Medicine and Pathology, University of Washingtongrid.34477.33, Seattle, Washington, USA.\', \'Basic Sciences Division, Fred Hutch Cancer Research Center, Seattle, Washington, USA.\', \'Department of Population Health Sciences, Albany College of Pharmacy and Health Sciencesgrid.413555.3, Albany, New York, USA.\', \'Department of Microbiology and Immunology, School of Medicine, University of North Carolina at Chapel Hillgrid.10698.36, Chapel Hill, North Carolina, USA.\', \'Duke Human Vaccine Institute, Duke Universitygrid.26009.3d School of Medicine, Durham, North Carolina, USA.\', \'Department of Surgery, Duke Universitygrid.26009.3d, Durham, North Carolina, USA.\']
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}